Titan pharmaceuticals steroids

We are a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Our product development programs utilize our proprietary long-term drug delivery platform, ProNeura(TM), and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Probuphine®, our first product candidate based on the ProNeura platform, was approved by the United States Food and Drug Administration, or FDA, on May 26, 2016 for the maintenance treatment of opioid dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. We have licensed development and commercialization rights of Probuphine for the . and Canadian markets to Braeburn Pharmaceuticals, Inc.  ... More ...  

Titan Pharmaceuticals Inc. ( TTNP ) had a rough trading day for Thursday January 18 as shares tumbled %, or a loss of $- per share, to close at $. After opening the day at $, shares of Titan Pharmaceuticals Inc. traded as high as $ and as low as $. Volume was 333,933 shares over 503 trades, against an average daily volume of 189,026 shares and a total float of million. As a result of the decline, Titan Pharmaceuticals Inc. now has a market cap of $ million. In the last year, shares of Titan Pharmaceuticals Inc. have traded between a range of $ and $, and its 50-day SMA is currently $ and 200-day SMA is $.

Titan pharmaceuticals steroids

titan pharmaceuticals steroids


titan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroids